Six months after starting a Phase II osteoporosis trial with BA058, Radius Health Inc. granted an option to Novartis AG for exclusive, worldwide rights to the drug outside of Japan. Novartis will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results